EUVIMEDEUVIMED entdecken
Crossref

Discovery of a Novel Potent and Orally Efficacious PROTAC Degrader of HPK1 for Tumor Immunotherapy

Jun Tong, Kaizhen Wang, Chenyi Liu, Lin Wang, Qi Miao, Yuxing Wu, Zhiyi Zhang, Zepeng Liao, Sheng Jiang iD, Ruo Wang, Yibei Xiao, Kuojun Zhang iD

Journal of Medicinal Chemistry · 14.08.2025 · 68 (15) · 15991-16017

DOI: 10.1021/acs.jmedchem.5c00970 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 30.07.2025. Verfasst von Jun Tong und 11 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, China Pharmaceutical University, Nanjing 210009, China. Hauptthemen laut MEDLINE: Immunotherapy, Protein Serine-Threonine Kinases, Antineoplastic Agents, Drug Discovery. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 61 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Jiangsu Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Hematopoietic progenitor kinase 1 (HPK1), a negative regulator of the TCR signaling pathway, has emerged as an attractive drug target for tumor immunotherapy. Herein, we report the discovery of a series of pyrazine-based HPK1 PROTAC degraders. The representative compound 10m demonstrated potent and sustained HPK1 degradation (DC50 = 5.0 ± 0.9 nM; Dmax ≥ 99%). Upon TCR activation, 10m significantly inhibited SLP76 phosphorylation and enhanced ERK pathway activation through degrading HPK1, thereby stimulating IL-2 and IFN-γ release. Furthermore, 10m exhibited the ability to overcome the immunosuppressive effects imposed by PGE2, NECA or TGF-β. Notably, orally administration of 10m alone efficaciously inhibited tumor growth in an MC38 syngeneic mouse model. Moreover, 10m achieved a superior antitumor effect when combined with PD-1 blockade, suggesting the complementarity between the two treatment modalities. Overall, this work provides promising lead compounds for the clinical development of HPK1 PROTACs as small-molecule therapeutics in tumor immunotherapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ImmunotherapyProtein Serine-Threonine KinasesAntineoplastic AgentsDrug DiscoveryPyrazinesAnimalsMiceHumansAdministration, OralCell Line, TumorMice, Inbred C57BLStructure-Activity RelationshipProteolysisFemale

Substanzen

hematopoietic progenitor kinase 1Protein Serine-Threonine KinasesAntineoplastic AgentsPyrazines

Autor:innen und Institutionen

  • School of Pharmacy, China Pharmaceutical University, Nanjing 210009, China.
  • Shengli Clinical Medical College of Fujian Medical University, Department of Breast Surgery, Fujian Provincial Hospital, Fuzhou University Affiliated Provincial Hospital, Fuzhou University, Fuzhou 350001, China.

ORCID-Profile: Sheng Jiang, Kuojun Zhang

Förderung

  • National Natural Science Foundation of China
  • Natural Science Foundation of Jiangsu Province

Zitieren

APA

Tong, J., Wang, K., Liu, C., Wang, L., Miao, Q., Wu, Y., Zhang, Z., Liao, Z., Jiang, S., Wang, R., Xiao, Y., & Zhang, K. (2025). Discovery of a Novel Potent and Orally Efficacious PROTAC Degrader of HPK1 for Tumor Immunotherapy. Journal of Medicinal Chemistry, 68(15), 15991-16017. https://doi.org/10.1021/acs.jmedchem.5c00970

Vancouver

Tong J, Wang K, Liu C, Wang L, Miao Q, Wu Y, et al. Discovery of a Novel Potent and Orally Efficacious PROTAC Degrader of HPK1 for Tumor Immunotherapy. Journal of Medicinal Chemistry. 2025;68(15):15991-16017. doi:10.1021/acs.jmedchem.5c00970

BibTeX
@article{Tong2025,
  author = {Tong, Jun and Wang, Kaizhen and Liu, Chenyi and Wang, Lin and Miao, Qi and Wu, Yuxing and Zhang, Zhiyi and Liao, Zepeng and Jiang, Sheng and Wang, Ruo and Xiao, Yibei and Zhang, Kuojun},
  title = {Discovery of a Novel Potent and Orally Efficacious PROTAC Degrader of HPK1 for Tumor Immunotherapy},
  journal = {Journal of Medicinal Chemistry},
  year = {2025},
  volume = {68},
  number = {15},
  pages = {15991--16017},
  doi = {10.1021/acs.jmedchem.5c00970}
}
Kostenlos starten →